Bessemer Group Inc. grew its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 100.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 301,008 shares of the biopharmaceutical company’s stock after purchasing an additional 150,699 shares during the quarter. Bessemer Group Inc.’s holdings in ACADIA Pharmaceuticals were worth $6,065,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently made changes to their positions in ACAD. BlackRock Inc. bought a new position in shares of ACADIA Pharmaceuticals during the second quarter worth approximately $569,634,000. First Trust Advisors LP lifted its holdings in ACADIA Pharmaceuticals by 47.3% during the 1st quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock worth $74,435,000 after purchasing an additional 1,073,834 shares during the last quarter. Palo Alto Investors LP bought a new stake in ACADIA Pharmaceuticals in the 2nd quarter valued at $72,461,629. Dimensional Fund Advisors LP boosted its stake in ACADIA Pharmaceuticals by 8.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock valued at $70,222,000 after purchasing an additional 234,186 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in ACADIA Pharmaceuticals by 12.5% in the 1st quarter. Renaissance Technologies LLC now owns 1,724,196 shares of the biopharmaceutical company’s stock valued at $38,381,000 after purchasing an additional 191,600 shares during the period. Institutional investors own 96.71% of the company’s stock.
ACADIA Pharmaceuticals Stock Performance
NASDAQ ACAD opened at $17.59 on Friday. The firm’s fifty day moving average price is $21.01 and its two-hundred day moving average price is $23.22. The stock has a market cap of $3.04 billion, a PE ratio of 8.34 and a beta of 0.87. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $15.85 and a fifty-two week high of $30.96.
Insider Buying and Selling at ACADIA Pharmaceuticals
In other news, EVP Mark Schneyer sold 3,321 shares of the company’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $20.88, for a total value of $69,342.48. Following the completion of the transaction, the executive vice president owned 71,322 shares of the company’s stock, valued at $1,489,203.36. This represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 26.20% of the company’s stock.
Analyst Ratings Changes
Several research analysts have weighed in on ACAD shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research report on Tuesday, November 10th. Canaccord Genuity Group upped their price target on shares of ACADIA Pharmaceuticals from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Citizens Jmp decreased their price target on shares of ACADIA Pharmaceuticals from $36.00 to $33.00 and set a “market outperform” rating on the stock in a research note on Friday, September 25th. Wall Street Zen lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 4th. Finally, TD Cowen reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, September 24th. Thirteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.13.
Read Our Latest Research Report on ACAD
ACADIA Pharmaceuticals Profile
ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.
Further Reading
- Five stocks we like better than ACADIA Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report).
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
